WHO Sounds Alert Over Acute Shortage of Obesity Jabs
Less than 10% of people who could benefit from GLP-1 drugs such as Wegovy can access them, warns the global health agency as it issues its first recommendations on the therapies.
Given over a billion individuals worldwide now obese, it is calling for increased and just availability to this class of drugs.
According to estimates, over two billion are projected to be living with obesity by 2030 if no action is taken.
"Our new guidance recognises that excess weight is a long-term condition that can be addressed with holistic and ongoing treatment," stated its chief Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and supply-chain constraints are significant barriers to widespread access to the injections that can aid individuals in losing considerable body mass, notes the agency.
Weight-Loss Drug Scarcity
Even under the present most optimistic case, the manufacturing of these medications might only reach around 100 million people – fewer than 10% of the global need, according to the health organization.
The advice calls on countries and companies to increase availability, by approaches such as patent sharing.
Exclusive production rights on a key compound – the main ingredient of a leading brand – is due to expire in a number of nations in 2026.
How Weight-Loss Injections Function
GLP-1 drugs replicate a natural hormone to slow digestion, curb appetite and boost the sense of being full so users consume fewer calories.
Individuals typically see weight reduction within a few weeks of commencing the once-weekly jabs.
Studies suggests people may regain a significant portion a year later of halting the drug, as their usual food cravings return.
To be overweight or obese elevates your chance for developing medical conditions, like diabetes, heart disease, brain attack, and certain cancers.
Excess weight impacts people in every country and was linked to over three and a half million fatalities worldwide in 2024, according to the WHO.
